Clinical Trial Update: Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial update reports that pioglitazone reduced left ventricular mass in patients with type 2 diabetes mellitus and ischemic heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Actos (Pioglitazone)

Snippet

Sponsor: Xiang Guang-da | Conditions: LVM, Type 2 Diabetic Patients With IHD | Phase 4 | Status: COMPLETED